Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BFH772 1% · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BFH772 | EXPERIMENTAL | - |
| Vehicle | PLACEBO_COMPARATOR | - |
| Metronidazole | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BFH772 1% ointment | DRUG | - |
| Vehicle ointment | DRUG | - |
| Noritate® 1% cream | DRUG | - |
Inclusion Criteria: * Have persistent facial erythema on the cheeks of at least moderate severity. * Women must not be able to bear children Exclusion Criteria: * Have more than 12 inflammatory lesions on the face * Previous treatment of facial skin with lasers or electrocauterisation within 2 mo...
BFH772 1% is an investigational small molecule being studied for the treatment of erythemato-telangiectatic rosacea, a form of rosacea characterized by redness and visible blood vessels. It is applied topically at a 1% concentration. The drug is not approved and remains in clinical development.
BFH772 1% is being developed by Novartis AG, a global pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical research to evaluate the safety and efficacy of this topical treatment for erythemato-telangiectatic rosacea.
BFH772 1% is in Phase 2 clinical development. A Phase 2 trial has been completed, but the drug remains investigational and has not received FDA approval. Further studies would be needed to establish its safety and efficacy before any regulatory submission.
BFH772 1% has been studied in one completed Phase 2 clinical trial, identified as NCT01449591. This randomized, double-blind, placebo-controlled study enrolled 36 participants with erythemato-telangiectatic rosacea in the United States. The trial evaluated the safety, tolerability, and efficacy of the treatment.
No, BFH772 1% is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for erythemato-telangiectatic rosacea. The completed Phase 2 trial represents early-stage research, and the drug has not yet been submitted for regulatory approval.